Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross HER2 Coverage & Prior Auth Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedPremera BluecrossPolicy 5.01.514

    HER2 Inhibitors (Pharmacy / Medical Policy)

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.514 alerts

    Get alerted when Policy 5.01.514 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical and pharmacy coverage criteria, documentation, coding, and authorization guidance for HER2-targeted therapies for oncology indications; intended for providers and prior authorization reviewers.

    Policy Summary
    PayerPremera Bluecross
    PolicyHER2 Inhibitors (Pharmacy / Medical Policy)
    Policy CodePolicy 5.01.514
    Change TypeMultiple material additions and revisions (coverage expansions, biosimilar preference updates, authorization period changes)
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateAug 1, 2026
    Key ActionObtain prior authorization and document HER2 status and prior therapy; initial approvals for oral drugs may be granted up to 6 months.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Hernexeos for adults with unresectable or metastatic non-squamous NSCLC harboring HER2 TKD activating mutations who have received prior systemic therapy.

    Updated Enhertu coverage to include treatment of certain unresectable or metastatic solid tumors and added a new indication for HR-positive HER2-low or HER2-ultralow breast cancer progressed on endocrine therapy.

    Updated Tukysa (tucatinib) colorectal cancer coverage criteria and added a quantity limit requirement.

    Updated trastuzumab biosimilar and product preference statuses (Ogivri preferred; other trastuzumab products moved to require trial of preferred agents).

    Updated Enhertu (fam-trastuzumab deruxtecan-nxki) coverage criteria to include treatment of certain individuals with an unresectable or metastatic solid tumor, and later added an indication for HR-positive HER2-low or HER2-ultralow breast cancer progressed on endocrine therapy.

    Added Hercessi (trastuzumab-strf) as a second line trastuzumab product and updated Ogivri (trastuzumab-dkst) from non-preferred to preferred.

    Added coverage criteria for Hernexeos (zongertinib) for adults with unresectable/metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy, and later removed ECOG 0–1 requirement.

    Added coverage criteria for Perjeta (pertuzumab) when used in combination with Enhertu for first-line treatment of unresectable or metastatic HER2-positive breast cancer or after progression on hormone therapy.

    Added coverage criteria for Hyrnuo (sevabertinib) for adults with locally advanced/metastatic non-squamous NSCLC with HER2 exon 20 insertion mutation after prior systemic therapy.

    Initial authorization period for all oral drugs listed in the policy was changed from 3 months to 6 months.

    Poherdy (pertuzumab-dpzb) was added to the policy with the same criteria as Perjeta (pertuzumab).

    Manyindividual HER2-targeted drugs listed (oral and injectable)
    6 monthsinitial approval for oral drugs
    12 monthsre-authorization period (injectable)
    1 yearrecommended adjuvant trastuzumab duration
    multipletrastuzumab biosimilars listed
    N/AMedicare Advantage

    Coverage Criteria for HER2-Targeted Therapies

    Hernexeos (zongertinib) — unresectable/metastatic non-squamous NSCLC

    Covered when ALL of the following are met

    Hernexeos criteria: The individual is aged 18 years or older; has unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) with a confirmed HER2 (ERBB2) tyrosine kinase domain activating mutation; Hernexeos (zongertinib) is administered as monotherapy; medication is prescribed by or in consultation with an oncologist; dose limited per weight (less than 90 kg: 120 mg once daily; greater than 90 kg: 180 mg once daily).weight-based dosing

    Hyrnuo (sevabertinib) — locally advanced/metastatic non-squamous NSCLC

    Covered when ALL of the following are met

    Hyrnuo criteria: The individual is aged 18 years or older; has locally advanced or metastatic non-squamous NSCLC with a confirmed HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation (exon 20 insertion); has received prior systemic therapy; Hyrnuo (sevabertinib) is administered as monotherapy; medication is prescribed by or in consultation with an oncologist; dose limited to 20 mg twice daily.
    Policy Summary
    PayerPremera Bluecross
    PolicyHER2 Inhibitors (Pharmacy / Medical Policy)
    Policy CodePolicy 5.01.514
    Change TypeMultiple material additions and revisions (coverage expansions, biosimilar preference updates, authorization period changes)
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateAug 1, 2026
    Key ActionObtain prior authorization and document HER2 status and prior therapy; initial approvals for oral drugs may be granted up to 6 months.
    SourceLink
    On This Page
    Coverage Criteria for HER2-Targeted TherapiesProvider Requirements, Prior Authorization, and DocumentationHCPCS / J-Codes and Related Coding ReferencesInitial Therapy Criteria and Evidence SummaryRe-Authorization and Continuation CriteriaStep Therapy and Sequencing RequirementsQuantity Limits and Dosing ConstraintsAdministration Site and SettingBiosimilar Preferences and Formulary SequencingBackground — HER2 Biology and Therapeutic ClassesKey Definitions and TermsSite-of-Care, Benefit Assignment, and Plan LimitsPolicy Update History
    20 mg twice daily

    Lapatinib (generic or Tykerb) — HER2-positive breast cancer

    Covered when ONE of the following AND dose limits met

    Lapatinib use cases: Use in combination with capecitabine for individuals with advanced or metastatic HER2-positive breast cancer who previously received an anthracycline, a taxane, and trastuzumab and progressed on trastuzumab; OR use in combination with letrozole for postmenopausal, hormone receptor–positive metastatic disease that overexpresses HER2 when hormonal therapy is indicated; dosing limits: generic lapatinib up to 1,500 mg/day or Tykerb (lapatinib) up to 600 mg/day (300 mg twice daily), and Tykerb requires prior inadequate response or intolerance to generic lapatinib.1500 mg/day or 600 mg/day

    Nerlynx (neratinib) — extended adjuvant and metastatic uses

    Covered when ALL of the following are met (separate pathways for extended adjuvant vs metastatic)

    Extended adjuvant neratinib: The individual is aged 18 years or older; has stage I–III breast cancer that overexpresses or has amplified HER2; neratinib (Nerlynx) is used as extended adjuvant therapy following completion of adjuvant trastuzumab-based therapy; dose limited to 240 mg (six tablets) per day; total duration limited to a maximum of 1 year when used as extended adjuvant treatment.240 mg/day; max 1 year
    Metastatic neratinib: The individual is aged 18 years or older; has stage III or IV HER2-positive breast cancer; has received two or more prior anti-HER2 regimens in the metastatic setting; neratinib is used in combination with capecitabine; dose limited to 240 mg (six tablets) per day.240 mg/day

    Tukysa (tucatinib) — breast and colorectal cancer

    Covered when ALL of the following are met for each indication

    Tucatinib for HER2-positive breast cancer: The individual is aged 18 years or older; has received one or more prior anti-HER2 regimens in the metastatic setting; tucatinib (Tukysa) is used in combination with trastuzumab and capecitabine; dose limited to 600 mg per day (300 mg twice daily); includes individuals with brain metastases.600 mg/day
    Tucatinib for unresectable/metastatic colorectal cancer: The individual is aged 18 years or older; has unresectable or metastatic colorectal cancer that is RAS wild-type and HER2-positive (IHC 3+ OR IHC 2+ with FISH overexpression or NGS amplification); disease progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; tucatinib is used in combination with trastuzumab; dose limited to 600 mg per day (300 mg twice daily).600 mg/day

    Quantity-limit requirement applies per policy updates.

    Trastuzumab products (IV biosimilars and Herceptin Hylecta) — breast, colorectal, gastric

    Covered when ALL of the following are met depending on indication

    Trastuzumab biosimilars first-line: Preferred IV trastuzumab biosimilars (e.g., Kanjinti, Ogivri, Trazimera, others) may be used for adjuvant, neoadjuvant, and metastatic HER2-positive breast cancer per regimen-specific indications; also used in combination with tucatinib for RAS wild-type, HER2-positive colorectal cancer after prior chemotherapy; and in combination with platinum and fluoropyrimidine agents for metastatic gastric/gastroesophageal adenocarcinoma consistent with trial regimens.
    Herceptin Hylecta sequencing: Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) may be used subcutaneously when there is inadequate response or intolerance to listed IV biosimilars or when difficult venous access is documented; administered by a healthcare professional.

    Kadcyla (ado-trastuzumab emtansine) — metastatic and early breast cancer

    Covered when ALL of the following are met (distinct metastatic vs adjuvant residual disease criteria)

    Kadcyla metastatic: Ado-trastuzumab emtansine (Kadcyla) used as a single agent for HER2-positive metastatic breast cancer in individuals who previously received trastuzumab and a taxane; individual either received prior treatment for metastatic disease or developed recurrent disease during or within 6 months of completing adjuvant therapy; dosing per trial 3.6 mg/kg IV every 3 weeks.3.6 mg/kg q3w

    EMILIA trial showed improved PFS and OS versus lapatinib plus capecitabine.

    Kadcyla adjuvant residual disease: Ado-trastuzumab emtansine used as adjuvant treatment for HER2-positive early breast cancer in individuals with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

    Enhertu (fam-trastuzumab deruxtecan-nxki) — multiple indications

    Covered when ALL criteria for specific indications are met

    Enhertu early breast neoadjuvant/adjuvant: Enhertu (fam-trastuzumab deruxtecan-nxki) used as neoadjuvant treatment for HER2-positive (IHC 3+ or ISH+) Stage II–III breast cancer followed by taxane, trastuzumab, and pertuzumab (THP), or as adjuvant treatment for residual invasive disease after neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based therapy.
    Enhertu metastatic HER2-positive: Enhertu used in unresectable or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH+) breast cancer either in combination with pertuzumab as first-line OR as monotherapy for individuals with prior anti-HER2 regimens in the metastatic or peri-adjuvant setting with recurrence during or within 6 months of completing therapy.
    Enhertu HER2-low HR-positive: Enhertu used for unresectable or metastatic HR-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow disease when cancer progressed on one or more endocrine therapies; prior chemotherapy in the metastatic setting or recent recurrence after adjuvant chemo required.
    Enhertu other tumor types: Enhertu covered for unresectable/metastatic HER2-positive gastric/gastroesophageal adenocarcinoma and for HER2-positive solid tumors with prior systemic treatment and no satisfactory alternative; also for NSCLC with activating HER2 mutations after prior systemic therapy.

    Margenza (margetuximab) and Pertuzumab products

    Covered when ALL criteria are met per indication

    Margenza: Margetuximab (Margenza) for individuals aged 18 years or older with metastatic HER2-positive breast cancer who received two or more prior anti-HER2 regimens (at least one for metastatic disease); used in combination with chemotherapy.
    Perjeta/Poherdy: Pertuzumab products (Perjeta, Poherdy) used in combination with trastuzumab and chemotherapy (docetaxel or paclitaxel) for neoadjuvant, adjuvant, or metastatic treatment of HER2-positive breast cancer; can be combined with trastuzumab products and may be used in combination with Enhertu for unresectable/metastatic HER2-positive disease.

    Approval durations and investigational statement

    Approval lengths: Initial authorization: oral drugs up to 6 months; re-authorization: oral and injectable drugs may be approved up to 12 months if drug-specific coverage criteria are met and clinical response is documented.6 months initial oral; 12 months re-authorization

    All other uses are investigational.

    Coverage criteria summary

    Covered when ALL of the following are met (clinical context and monitoring):

    HER2 testing and selection: HER2 overexpression or amplification must be demonstrated by validated IHC or FISH assay performed by a laboratory with demonstrated proficiency; acceptable assays include HercepTest, Pathway HER2/neu (IHC), PathVysion and HER2 FISH pharmDx (FISH).IHC or FISH positive per assay-specific criteria
    Cardiac baseline and monitoring: Baseline left ventricular ejection fraction (LVEF) must be within the treating institution's normal range before initiating trastuzumab or related agents, and periodic monitoring (e.g., at 3, 6, and 12 months) must be documented; therapy continuation depends on absence of an unacceptable decrease (e.g., greater than 15% from baseline).>15% decrease

    EMILIA required LVEF >=50%

    Agent-specific benefit assignment: Certain small-molecule HER2 inhibitors (e.g., zongertinib, sevabertinib, lapatinib, neratinib, tucatinib) are managed under the pharmacy benefit while monoclonal antibodies and ADCs (trastuzumab products, pertuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan) are medical benefit-managed; benefit assignment may determine prior authorization pathway.
    Adjuvant trastuzumab duration: Evidence supports approximately 1 year of adjuvant trastuzumab as standard of care; trials comparing 2 years to 1 year did not show improved effectiveness and were associated with more adverse events.1 year

    PHARE and HERA trial results and meta-analysis summarized.

    Adjuvant/Neoadjuvant therapy coverage

    Adjuvant and neoadjuvant trastuzumab covered when clinical trial evidence supports benefit for HER2-positive patients with high-risk or node-positive disease; neoadjuvant use is considered medically necessary when given with neoadjuvant chemotherapy for HER2-positive patients with operable, high-risk tumors.

    Adjuvant trastuzumab typical candidate: Patient has HER2-positive breast cancer and disease is node-positive or high-risk node-negative (trials excluded small <1 cm node-negative tumors); trastuzumab is administered as part of adjuvant therapy, commonly for a duration of approximately 1 year.

    Trials demonstrated improved DFS and OS; small node-negative tumors were excluded from trials.

    Ado-trastuzumab emtansine (T-DM1) — metastatic/advanced

    Ado-trastuzumab emtansine (T-DM1) coverage for metastatic HER2-positive breast cancer after prior trastuzumab and a taxane, based on EMILIA trial.

    Ado-trastuzumab emtansine (EMILIA population): Patient has unresectable, locally advanced or metastatic HER2-positive breast cancer AND previously treated with trastuzumab and a taxane AND dosing planned as ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks.3.6 mg/kg q3w

    EMILIA showed improved PFS and OS versus lapatinib+capecitabine.

    Lapatinib (Tykerb) — metastatic disease

    Lapatinib plus capecitabine has evidence for use in HER2-positive metastatic breast cancer after prior therapies.

    Lapatinib + capecitabine eligible population: Patient has HER2-overexpressing locally advanced or metastatic breast cancer progressing after prior anthracyclines, taxanes, and trastuzumab; lapatinib combined with capecitabine has demonstrated improved time to progression versus capecitabine alone.

    Gastric/gastroesophageal cancer

    Trastuzumab use in gastric/gastroesophageal adenocarcinoma based on one Phase III trial.

    Trastuzumab in advanced gastric/gastroesophageal cancer: Patient has HER2-positive locally advanced, recurrent, or metastatic gastric/gastroesophageal adenocarcinoma AND trastuzumab is given with chemotherapy as in the pivotal trial (every 3 weeks for up to 6 cycles or until progression).

    Phase III trial showed median OS 13.8 vs 11.1 months (HR 0.74).

    Recent Additions and Revisions

    Policy updates and additions (history notes) — new and revised covered indications and administrative rules

    Poherdy addition: Poherdy (pertuzumab-dpzb) has been added to the policy with the same criteria as Perjeta (pertuzumab).

    Added per history effective 08/01/26.

    Enhertu neoadjuvant/adjuvant expansion: Enhertu (fam-trastuzumab deruxtecan-nxki) coverage expanded to include HER2-positive Stage II–III breast cancer as neoadjuvant treatment followed by THP, and adjuvant treatment for residual invasive disease after neoadjuvant trastuzumab (with or without pertuzumab) and taxane therapy.

    Added per history notes.

    Oral drug authorization duration: Initial authorization for oral drugs listed in the policy changed from 3 months to 6 months.

    Applies to oral drugs in this policy.

    Hyrnuo coverage: Hyrnuo (sevabertinib) criteria added for adults with locally advanced or metastatic NSCLC harboring HER2 TKD activating mutations; Hyrnuo is administered as monotherapy.
    Hernexeos criteria update: Hernexeos (zongertinib) criteria were updated to remove the ECOG performance status requirement and to modify prior systemic therapy requirements in a subsequent revision.

    All other uses of the medications listed in this policy are considered investigational. Coverage is limited to the indications and criteria described in this policy and medications are subject to the product's FDA dosage and administration prescribing information.

    Ado-trastuzumab emtansine (Kadcyla) is associated with known gestational adverse effects and should not be used in pregnant women. Effective contraception is recommended during treatment and for at least 7 months after treatment.

    Adjuvant trastuzumab trials excluded individuals with small (<1 cm) node-negative tumors; therefore there is no evidence of benefit for routine adjuvant trastuzumab in that subgroup and coverage is not supported by the trial data.

    Additional notable exclusions and safety notes: policy updates clarify that medications are subject to the product's FDA dosing and administration information and non-formulary exception reviews may be approved for up to 12 months. Ado-trastuzumab emtansine has specific safety concerns including hepatotoxicity, decreases in left ventricular ejection fraction, and pediatric safety not established; these safety issues inform contraindications and monitoring requirements. Finally, outside the listed, evidence-based indications, uses are considered investigational.

    Clinical monitoring and documentation notes: HER2 overexpression must be demonstrated by validated IHC or FISH testing performed by a proficient laboratory, and baseline cardiac function (left ventricular ejection fraction within the treating institution's normal range) with periodic cardiac monitoring must be documented. The timing of initiation and sequencing of trastuzumab relative to adjuvant chemotherapy remains an unresolved issue in the literature and should be considered when applying criteria.

    This medical policy is not applicable to Medicare Advantage. Coverage decisions described in this policy are subject to the limits and conditions of the member's benefit plan and reviewers should confirm benefit applicability using the member benefit booklet or customer service as needed.

    Timing and uncertainty: use of trastuzumab or other HER2-targeted therapy outside trial-tested timeframes (for example, initiating treatment long after completion of adjuvant chemotherapy) remains uncertain because these populations were not formally studied; such off‑trial adjuvant chemotherapy or delayed initiation may be considered investigational or require additional review and documentation.

    Evidence in non-breast, non-gastric cancers is limited. Small, uncontrolled series or phase II reports in ovarian, salivary gland, urothelial, bladder, renal pelvis, and non‑small cell lung cancers have shown low or inconsistent activity; routine use of trastuzumab outside breast or gastric/gastroesophageal adenocarcinoma is not supported by robust randomized data and is not standard care.

    No explicit 'not medically necessary' statements are provided in the document segments cited. Where uses are unsupported by evidence they are described as investigational rather than explicitly labeled 'not medically necessary' in these sections.

    No explicit 'not medically necessary' statements are present in the cited sections; reviewers should rely on the investigational designation and the covered-with-criteria sections to determine coverage versus non‑coverage.

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization and approval durations

    Prior authorization is required for drugs in this policy. Initial approvals for oral drugs may be granted for up to 6 months; re-authorizations for oral and injectable drugs may be approved for up to 12 months if drug-specific coverage criteria are met and chart notes demonstrate continued clinical benefit.

    • Initial authorization: oral drugs — up to 6 months.
    • Re-authorization: oral and injectable drugs — may be approved up to 12 months with documentation of continued benefit.
    Note

    Check pharmacy vs medical benefit assignment

    Determine benefit assignment before submitting authorization: some HER2-targeted small-molecule agents are managed under the pharmacy benefit while monoclonal antibodies, ADCs, and most trastuzumab products are managed under the medical benefit; prior authorization pathways follow that assignment.

    • Pharmacy benefit examples: Hernexeos (zongertinib), Hyrnuo (sevabertinib), lapatinib, neratinib, tucatinib.
    • Medical benefit examples: Enhertu, trastuzumab products, ado-trastuzumab emtansine, pertuzumab and pertuzumab-containing products.
    Prior Authorization

    Confirm prior therapy and trial-consistent dosing

    For agents with trial-based eligibility (eg, ado‑trastuzumab emtansine), prior authorization must document prior therapies and dosing consistent with trial criteria and labeling — specifically prior trastuzumab and a taxane and planned dosing of ado‑trastuzumab emtansine 3.6 mg/kg IV every 3 weeks when indicated.

    • Confirm prior exposure to trastuzumab and a taxane as required by EMILIA trial-derived criteria.
    • Document planned dosing schedule (ado‑trastuzumab emtansine 3.6 mg/kg IV q3w) when applicable.
    Prior Authorization

    Prior authorization required for HER2-targeted agents

    Obtain prior authorization for all HER2-targeted therapies in this policy; coverage changes, biosimilar/ preferred-product designations, and quantity limits (eg, for tucatinib) require approvals consistent with the policy criteria.

    • Submit authorization requests consistent with the most recent product preference and quantity-limit updates.
    • Non-formulary exception requests follow standard review (see exception review block).
    Prior Authorization

    Prior authorization and non‑formulary exception review

    Certain non‑preferred trastuzumab products and other HER2 agents require prior authorization and may require documentation of trials with preferred products or a non‑formulary exception; non‑formulary exception approvals may be granted for up to 12 months and prescriptions must follow FDA dosing/administration.

    • Non-preferred trastuzumab products: require trial of all preferred trastuzumab products prior to approval.
    • Non‑formulary exceptions: can be approved up to 12 months; must follow FDA dosing/administration information.
    Prior Authorization

    Initial authorization period — oral drugs

    Note the updated initial authorization period: initial approvals for oral drugs in this policy were changed from 3 months to 6 months; use this period when requesting first-time authorizations for oral agents.

    • Apply 6-month initial approval window for oral HER2-targeted agents listed in the policy.
    Step Therapy

    Formulation sequencing — Herceptin Hylecta requirements

    Herceptin Hylecta (subcutaneous trastuzumab + hyaluronidase) is only authorized after documentation of inadequate response or intolerance to listed IV trastuzumab biosimilars, except when difficult venous access is documented; Hylecta must be administered by a healthcare professional (subcutaneous administration).

    • Require documentation of inadequate response or intolerance to IV biosimilars (Kanjinti, Ogivri, Trazimera) before approving Hylecta, unless difficult venous access is shown.
    • Hylecta is administered subcutaneously and must be given by a health-care professional.
    Note

    Document sequencing — concurrent vs sequential trastuzumab

    When trastuzumab is given in the adjuvant setting, evidence favors concurrent administration with paclitaxel over sequential administration for improved disease‑free survival in at least one trial; include sequencing rationale in the authorization documentation when relevant.

    • Document whether trastuzumab will be given concurrently with chemotherapy (preferred per NCCTG N9831 interim results) or sequentially, and justify deviations from concurrent use.
    Note

    Therapy sequencing — prior-agent context for ado‑trastuzumab emtansine

    For agents used after prior HER2 therapy (eg, ado‑trastuzumab emtansine), ensure authorization documentation reflects the appropriate prior-agent context — EMILIA supported ado‑trastuzumab emtansine after prior trastuzumab and a taxane; cite prior regimen and timing in the request.

    • Specify prior trastuzumab and taxane exposure and whether the prior treatment was for metastatic disease or recurrence within adjuvant settings.
    • Reference the comparator/regimen used in pivotal trials (eg, lapatinib + capecitabine in EMILIA) when relevant to line of therapy.
    Step Therapy

    Trial of preferred trastuzumab products required

    Before authorizing a non‑preferred trastuzumab product, the provider must document trial and inadequate response or intolerance to all preferred trastuzumab products; failure to document such trials may result in denial.

    • Preferred-product examples referenced in history include Kanjinti and Trazimera when designated preferred.
    • If preferred agents were not tried, request should include rationale or a non‑formulary exception.
    Step Therapy

    Preferred-product trial — detailed documentation required

    If requesting coverage for a non‑preferred trastuzumab product, include documentation that all preferred trastuzumab products were tried and failed; the policy requires trial‑with of preferred agents prior to approval of non‑preferred products.

    • List dates and reasons for discontinuation/intolerance of each preferred trastuzumab product.
    • Attach infusion/administration records or prior authorization decisions showing prior use of preferred agents.
    Billing Rule

    Historical preferred/non‑preferred biosimilar rules

    Historically and currently the policy designates certain trastuzumab biosimilars as preferred while others are non‑preferred; verify the current preferred/non‑preferred status in the policy history and include evidence of trial/failure per that formulary placement when requesting non‑preferred agents.

    • History notes document changes in preferred status (eg, Ogivri moved between non‑preferred and preferred).
    • Provider requests must reflect the most recent designation in the policy.
    Documentation Required

    Required clinical documentation — general medical records

    Submit medical records to support medical necessity: include office visit notes with diagnosis, relevant history, physical exam, medication history, and any other records demonstrating that coverage criteria are met.

    • Include clinical notes that state the indication, prior therapies, treatment response, and plan.
    • Attach documentation of requests for trial of preferred agents when applicable.
    Documentation Required

    HER2 status and cardiac monitoring documentation

    Provide HER2 testing documentation performed by a laboratory with demonstrated proficiency (IHC or FISH) and baseline and periodic left ventricular ejection fraction (LVEF) measurements within the treating institution's normal range; continued therapy depends on absence of an unacceptable LVEF decline (eg, >15% from baseline).

    • Attach HER2 assay results (HercepTest, Pathway HER2/neu, PathVysion, or HER2 FISH pharmDx) and laboratory information.
    • Provide baseline LVEF and subsequent monitoring values (eg, 3, 6, 12 months) or explain monitoring plan.
    Documentation Required

    HER2 status and prior therapy documentation — gastric cancer

    For metastatic gastric/gastroesophageal cancer, include documentation of HER2‑positive status and prior chemotherapy regimen details to match the Phase III trial population used to support coverage.

    • Supply pathology/staining reports confirming HER2 overexpression/amplification and chemotherapy history (eg, platinum + fluoropyrimidine).
    Documentation Required

    Non‑formulary exception timing and FDA dosing adherence

    Non‑formulary exception requests may be approved for up to 12 months; include rationale for exception and confirm that prescriptions follow the product's FDA dosing and administration prescribing information.

    • State the reason preferred agents are not appropriate (intolerance, lack of efficacy, access issues).
    • Provide planned dosing consistent with FDA labeling.
    Documentation Required

    Dosage and exception documentation

    When requesting approval for off‑label dosing or durations, document adherence to the product's FDA dosing/administration information; non‑formulary exception reviews that deviate from labeled dosing require justification and are limited to up to 12 months if approved.

    • Include prescribing information excerpts or peer‑reviewed rationale when deviating from labeled dosing.
    • Non‑formulary exceptions follow the 12‑month maximum approval guidance.
    Prior Authorization

    Review authorizations — up to 12 months

    Authorization reviews for drugs in this policy may be approved for up to 12 months on review when criteria are met; ensure chart notes document ongoing positive clinical response to support re‑authorization.

    • For re‑authorization requests, include interval assessment notes documenting response, adverse events, and ongoing plan.
    Denial Risk

    Denial risk — missing documented HER2 alteration or prior therapy

    Authorizations may be denied if the diagnosis does not document the indicated HER2 alteration or if stated prior therapy requirements in the policy are not met; include pathology or molecular reports and prior treatment records to avoid denial.

    • Examples: absence of documented HER2 TKD activating mutation for NSCLC agents or missing prior systemic therapy when required.
    • Attach mutation report, pathology, and prior oncology treatment records.
    Denial Risk

    Triggers for potential denial

    Potential denial triggers include HER2 testing performed by a lab without demonstrated proficiency, missing baseline or periodic LVEF monitoring, or use of ado‑trastuzumab emtansine in pregnancy — provide testing facility information, cardiac monitoring records, and pregnancy status as applicable.

    • Confirm HER2 testing was performed by a proficient facility and attach assay report.
    • Provide baseline LVEF and periodic monitoring values; if missing, explain monitoring plan.
    • For ado‑trastuzumab emtansine, confirm the patient is not pregnant and document contraception counseling when relevant.
    Denial Risk

    Small node‑negative tumors exclusion — adjuvant trastuzumab limits

    Adjuvant trastuzumab trials excluded individuals with small (<1 cm) node‑negative tumors; absence of evidence of benefit for that subgroup may lead to denial for adjuvant use in tumors <1 cm — document tumor size and nodal status clearly when requesting adjuvant trastuzumab.

    • If tumor is <1 cm and node‑negative, include justification or evidence supporting use if requesting coverage.
    Denial Risk

    Denial risk — failure to trial preferred trastuzumab products

    Failure to document trial and inadequate response or intolerance to preferred trastuzumab products before requesting non‑preferred agents may result in denial or a requirement to complete step therapy; include prior trial records to support requests for non‑preferred trastuzumab products.

    • Document dates, doses, response, and reasons for discontinuation for each preferred trastuzumab product tried.
    • If unable to trial preferred agents, provide clinical rationale for exception.
    Step Therapy

    Formulary trial and exception limits — step therapy enforcement

    Step‑therapy enforcement: non‑preferred trastuzumab products require trial of all preferred trastuzumab products before coverage is approved; if the required trials are not documented, requests will be denied or returned for step‑therapy completion.

    • Preferred‑first enforcement applies to trastuzumab biosimilars and certain reference products per policy history.
    • Include prior authorization approvals or infusion records demonstrating preferred product use and failure.
    Billing Rule

    Confirm member benefit plan limits

    Coverage is subject to the member's benefit plan limits and conditions; verify member benefits and consult the member benefit booklet or customer service — services not covered under the member's plan may be denied regardless of medical necessity.

    • Confirm whether the policy applies to the member (note: policy does not apply to Medicare Advantage).
    • Contact member services or check benefit booklet for plan‑level coverage restrictions.

    HCPCS / J-Codes and Related Coding References

    HCPCS codes listedHCPCS
    J3590Unclassified biologics (use to report: Poherdy).
    J9306Injection, pertuzumab (Perjeta), 1 mg.
    J9307Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, (Phesgo) per 10 mg.
    J9353Injection, margetuximab-cmkb, (Margenza) 5 mg.
    J9354Injection, ado-trastuzumab emtansine (Kadcyla), 1 mg.
    J9355Injection, trastuzumab, excludes biosimilar, (Herceptin) 10 mg.
    J9356Injection, trastuzumab, 10 mg and hyaluronidase-oysk (Herceptin Hylecta).
    J9358Injection, fam-trastuzumab deruxtecan-nxki (Enhertu), 1 mg.
    Q5112Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg.
    Q5113Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg.
    1–10 of 14
    1/2
    Listed HER2 agents by benefit managementmixed
    Hernexeos (zongertinib)pharmacy-managed HER2 inhibitor listed
    Hyrnuo (sevabertinib)pharmacy-managed HER2 inhibitor listed
    lapatinibpharmacy-managed HER2 inhibitor listed
    Nerlynx (neratinib)pharmacy-managed HER2 inhibitor listed
    Tukysa (tucatinib)pharmacy-managed HER2 inhibitor listed
    Tykerb (lapatinib)pharmacy-managed HER2 inhibitor listed
    Enhertu (fam-trastuzumab deruxtecan-nxki)medical benefit-managed HER2 agent listed
    Herceptin (trastuzumab)medical benefit-managed HER2 agent listed
    Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)medical benefit-managed HER2 agent listed
    Hercessi (trastuzumab strf)medical benefit-managed HER2 agent listed
    1–10 of 20
    1/2
    HCPCS and historical coding referencesHCPCS
    J9316HCPCS code added for a trastuzumab product (referenced in history)
    J9353HCPCS code added (referenced in history)
    J9354HCPCS code added (referenced in history)
    J9356HCPCS code added (referenced in history)
    J9358HCPCS code added (referenced in history)
    Q5146HCPCS code added effective 1/1/2025
    J3590HCPCS code referenced (added/removed at times in history)
    inv-30: weight-based dosing threshold for Hernexeos
    Dose thresholds<90 kg: 120 mg once daily (2 tablets); >90 kg: 180 mg once daily (3 tablets)
    Indication ageAdults aged 18 years or older
    AdministrationOral, administered as monotherapy
    inv-31: Left ventricular ejection fraction (LVEF)
    Baseline requirementLeft ventricular ejection fraction (LVEF) should be measured before initiating therapy and be within the treating institution's normal range
    Monitoring frequencyPeriodic monitoring recommended (e.g., at 3, 6, and 12 months)
    Clinically significant change>15% decrease from baseline considered unacceptable
    EMILIA trial criterionEMILIA included individuals with LVEF ≥50%

    Initial Therapy Criteria and Evidence Summary

    Re-Authorization and Continuation Criteria

    Step Therapy and Sequencing Requirements

    RequirementDetails
    Try IV trastuzumab biosimilars first
    Kanjinti, Ogivri, Trazimera and other IV trastuzumab biosimilars are preferred first-line; subcutaneous Herceptin Hylecta may be used only after inadequate response or intolerance to the listed IV biosimilars (exception allowed for documented difficult venous access)
    Sequencing considerationEvidence summary
    Concurrent versus sequential trastuzumab with chemotherapy
    NCCTG N9831 six‑year interim results demonstrated longer disease‑free survival (DFS) with concurrent trastuzumab (with paclitaxel) versus sequential administration, supporting concurrent use when appropriate
    Placement in therapySupporting trial evidence / requirement
    Ado‑trastuzumab emtansine (T‑DM1) after prior trastuzumab and a taxane
    Phase III EMILIA: patients with unresectable or metastatic HER2‑positive breast cancer previously treated with trastuzumab and a taxane had improved PFS (9.6 vs 6.4 months) and OS (30.9 vs 25.1 months; HR 0.68) with ado‑trastuzumab emtansine versus lapatinib plus capecitabine
    Step requirementAuthorization implication
    Prior authorization requires trial of preferred trastuzumab products
    Non‑preferred trastuzumab products were updated to require documentation of trial and failure of preferred trastuzumab products before authorizing non‑preferred agents; failure to trial preferred agents may trigger denial or step‑therapy documentation requirement
    Preferred‑product trialPolicy detail
    Trial of all preferred trastuzumab products required before non‑preferred coverage
    Policy designates specific trastuzumab biosimilars as preferred (e.g., Kanjinti, Trazimera per updates) and requires an adequate trial and failure with preferred agents prior to coverage of non‑preferred trastuzumab products
    Examples (historical / formulary placement)Notes
    Moved Ogivri to preferred; Kanjinti and Trazimera changed to preferred in 2024 update
    Herceptin, Herceptin Hylecta, Hercessi, Herzuma, and Ontruzant were updated to non‑preferred and require trial/failure of preferred trastuzumab products; Herceptin Hylecta (subcutaneous) allowed only after inadequate response/intolerance to IV biosimilars or for difficult venous access

    Quantity Limits and Dosing Constraints

    inv-81: Tukysa (tucatinib) — quantity limit requirement added
    Quantity-limit statusQuantity limit requirement added for Tukysa (tucatinib)
    Affected indicationApplied to colorectal cancer coverage criteria per 2024 update
    Policy actionQuantity limit referenced in prescribing-information review and history
    inv-82: Tukysa (tucatinib) — colorectal cancer quantity limit
    IndicationRAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (tucatinib + trastuzumab)
    Quantity-limit noteQuantity limit requirement specifically added to the colorectal cancer coverage criteria (2024 update)
    Dose in trialTukysa 300 mg orally twice daily in combination with trastuzumab
    inv-83: Nerlynx (neratinib) dosing (240 mg — six tablets)
    Daily dose240 mg per day (six tablets)
    IndicationsExtended adjuvant neratinib after trastuzumab-based adjuvant therapy and metastatic use in combination with capecitabine per criteria
    Maximum duration (adjuvant)Total duration limited to a maximum of 1 year for extended adjuvant use

    Administration Site and Setting

    Billing Rule

    Herceptin Hylecta subcutaneous administration and professional administration requirement

    Herceptin Hylecta is administered subcutaneously and must be administered by a healthcare professional; prior authorization requirements for Hylecta follow the medical benefit rules when applicable.

    Note

    Administration site depends on benefit assignment

    Administration site depends on benefit assignment: pharmacy-managed oral agents are dispensed for outpatient use, while medical benefit monoclonal antibodies/ADCs are administered in medical settings (infusion center, office, or hospital outpatient).

    Billing Rule

    IV infusions administration and facility considerations

    Intravenous trastuzumab products and ado-trastuzumab emtansine are administered as IV infusions; ensure the facility or institutional setting is appropriate for IV biologic infusions and bill under the medical benefit.

    Note

    Infusion vs oral agent administration notes

    Infusions (IV biologics and ADCs) should be distinguished from oral agents for administration and billing; follow the product labeling for route of administration and benefit assignment when documenting site of care.

    Billing Rule

    Coverage under medical benefit and member plan limits

    Coverage for medical benefit‑managed agents is subject to the member's benefit plan limits and any site-of-care restrictions in the member's benefit booklet; verify coverage prior to service.

    Biosimilar Preferences and Formulary Sequencing

    Billing Rule

    Herceptin (trastuzumab) IV biosimilars preferred first-line; Herceptin Hylecta use after inadequate response/intolerance

    IV trastuzumab biosimilars (eg, Kanjinti, Ogivri, Trazimera) are preferred first-line under the medical benefit; Herceptin Hylecta (subcutaneous) may be used only after inadequate response or intolerance to listed IV biosimilars or for difficult venous access.

    Billing Rule

    Multiple trastuzumab biosimilars listed under medical benefit management

    Multiple trastuzumab biosimilars and reference products are listed and managed under the medical benefit; confirm the current preferred list when requesting authorization.

    Billing Rule

    Updated trastuzumab product moved from non-preferred to preferred

    Policy history shows Ogivri was updated from non-preferred to preferred; always verify current product status in the policy history before submitting requests for non-preferred agents.

    Billing Rule

    Updated trastuzumab products designated non-preferred requiring trial of preferred agents

    Some trastuzumab products were updated to non-preferred status requiring documented trials of all preferred trastuzumab products prior to coverage of the non-preferred product.

    Billing Rule

    Product status updated from non-preferred to preferred

    Policy history records show product status changes where agents moved from non-preferred to preferred; verify these historical changes when constructing authorization rationale.

    Billing Rule

    Added a second-line trastuzumab biosimilar product

    A second-line trastuzumab biosimilar (Hercessi) was added to the policy as a later-line product; include sequencing rationale if requesting second-line biosimilars.

    Billing Rule

    Trastuzumab reference products — preferred and non-preferred designations updated historically

    Preferred and non-preferred designations for trastuzumab reference products and biosimilars have been updated over time; check the policy history to ensure correct billing and step‑therapy documentation.

    Background — HER2 Biology and Therapeutic Classes

    Background: HER2 (ERBB2) is a receptor tyrosine kinase implicated in oncogenesis when amplified or overexpressed. HER2 alterations drive a subset of cancers—most prominently approximately 20–30% of breast cancers—and are actionable with multiple classes of agents including monoclonal antibodies, antibody–drug conjugates, and small‑molecule tyrosine kinase inhibitors. HER2-targeted therapies block HER2-driven signaling and have proven benefit in specific HER2-positive and select HER2-mutant or HER2-low contexts described in this policy.

    Key Definitions and Terms

    inv-57: HER2-low definition
    HER2-low definitionIHC 1+ OR IHC 2+ with negative ISH (diagnosed by IHC and sometimes ISH)
    Associated agent exampleEnhertu covered for HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy progression
    Diagnostic methodsPrimarily defined by immunohistochemistry (IHC), with ISH used to confirm negative amplification when IHC is 2+
    inv-58: HER2 definition
    HER2 (term)Human epidermal growth factor receptor 2 (HER2/ERBB2), a receptor tyrosine kinase implicated in oncogenesis when amplified or overexpressed
    Clinical relevanceHER2 is amplified/overexpressed in ~20–30% of breast cancers and is a target for multiple agents
    Other tumorsAlso overexpressed in ovarian, thyroid, lung, salivary gland, stomach, colon, and prostate cancers
    inv-59: HER2 testing methods (IHC, ISH)
    IHC assaysImmunohistochemistry assays include HercepTest and Pathway HER2/neu (used to assess HER2 overexpression)
    ISH/FISH assaysFluorescence in situ hybridization assays include PathVysion and HER2 FISH pharmDx (used to assess gene amplification)
    Laboratory proficiencyHER2 testing should be performed only by facilities with demonstrated proficiency in the specific assay
    inv-60: DFS definition
    DefinitionDisease-free survival (DFS) as reported in adjuvant trastuzumab trials
    Clinical useDFS used as a key endpoint in adjuvant trials demonstrating trastuzumab benefit
    Typical follow-upDFS reported in combined analyses of major adjuvant trastuzumab trials
    inv-61: OS definition
    DefinitionOverall survival (OS) — a primary or key secondary endpoint in multiple trials evaluating HER2-targeted therapies
    Evidence exampleCombined adjuvant trastuzumab trials showed significant OS improvement versus controls
    Use in trialsOS reported alongside DFS as key outcomes in randomized studies
    inv-62: Kadcyla (ado-trastuzumab emtansine) definition
    Agent classAdo-trastuzumab emtansine (Kadcyla) is an antibody–drug conjugate combining trastuzumab and emtansine (DM1)
    MechanismBinds HER2 and is internalized; proteolytic degradation releases the cytotoxic DM1 payload
    IndicationsUsed for metastatic HER2-positive breast cancer after prior trastuzumab and a taxane, and as adjuvant therapy for residual disease after neoadjuvant therapy per criteria
    inv-63: Tukysa (tucatinib) definition
    Agent classTucatinib (Tukysa) is an oral, small-molecule HER2 tyrosine kinase inhibitor (TKI)
    Typical combinationUsed in combination with trastuzumab for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer and for HER2-positive breast cancer per criteria
    Dose used in colorectal trial300 mg orally twice daily (600 mg/day)
    inv-64: Trastuzumab definition
    Agent classTrastuzumab is a humanized monoclonal antibody directed against the extracellular domain of HER2
    Regulatory statusFDA-approved for HER2-positive breast cancer in adjuvant and metastatic settings
    FormulationsAvailable as IV reference product and several biosimilars; subcutaneous Herceptin Hylecta also available
    inv-65: HER2-positive definition
    HER2-positive criteriaTumors with HER2 protein overexpression (IHC 3+) OR gene amplification (ISH positive)
    Agent relevanceHER2-positive status is required for coverage of many agents (e.g., Enhertu, Perjeta, trastuzumab products)
    Testing confirmationDetermination relies on validated IHC or ISH assays performed by proficient laboratories

    Site-of-Care, Benefit Assignment, and Plan Limits

    Note

    Coverage under the medical benefit and subject to member benefit plan limits

    Coverage under the medical benefit is subject to the member's benefit plan limits and conditions; verify the member's booklet for any applicable restrictions prior to service.

    Note

    Coverage subject to member benefit plan limits and conditions

    All coverage and prior authorization determinations remain subject to the member's benefit plan limits and conditions; services may be denied if not covered by the member's benefit booklet.

    Policy Update History

    2026-08-01policy_effective_dateLatest

    Policy effective date updated to 2026-08-01 with multiple interim revisions summarized in the history including additions of Poherdy and Enhertu neoadjuvant/adjuvant expansions.

    2026-05-01criteria_revision

    Updated coverage criteria for Hernexeos (zongertinib) removing the ECOG performance status requirement and modifying prior systemic therapy language.

    2026-02-01addition

    Added Enhertu plus pertuzumab as a first-line treatment option for unresectable or metastatic HER2-positive breast cancer and added Perjeta criteria when used in combination with Enhertu.

    2026-01-13annual_review

    Annual review completed with updates to prescribing information reviewed for all drugs in the policy.

    2025-11-01addition

    Added coverage criteria for Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy.

    2025-10-01formulary_update

    Ogivri (trastuzumab-dkst) updated from non-preferred to preferred; other non-preferred trastuzumab products were updated to require trial of preferred agents.

    2024-01-01addition

    Added Hercessi (trastuzumab-strf) as a second-line trastuzumab product and expanded Enhertu coverage to include certain unresectable or metastatic solid tumors.

    2025-11-01prior_authorization_addition

    Added prior authorization requirement updates including that certain non-preferred trastuzumab products require trial of all preferred trastuzumab products and Ogivri was moved to preferred status.

    2025-11-01exception_clarification

    Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months and that medications are subject to the product's FDA dosage and administration prescribing information.

    2026-08-01policy_effective_dateLatest
    2026-05-01authorization_duration_changeLatest

    Initial authorization period for all oral drugs listed in the policy was changed from 3 months to 6 months.

    Policy effective date 2026-08-01 reflects prior authorization and exception review updates made in 2024–2026, consolidated in the policy history.